JP2002533359A - 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入 - Google Patents

組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入

Info

Publication number
JP2002533359A
JP2002533359A JP2000590483A JP2000590483A JP2002533359A JP 2002533359 A JP2002533359 A JP 2002533359A JP 2000590483 A JP2000590483 A JP 2000590483A JP 2000590483 A JP2000590483 A JP 2000590483A JP 2002533359 A JP2002533359 A JP 2002533359A
Authority
JP
Japan
Prior art keywords
aav
cardiomyocytes
raav
use according
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000590483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002533359A5 (cg-RX-API-DMAC7.html
Inventor
ジェフリー エム. ライデン,
エリック スベンソン,
Original Assignee
アーチ ディベロップメント コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーチ ディベロップメント コーポレイション filed Critical アーチ ディベロップメント コーポレイション
Publication of JP2002533359A publication Critical patent/JP2002533359A/ja
Publication of JP2002533359A5 publication Critical patent/JP2002533359A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000590483A 1998-12-28 1999-12-28 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入 Pending JP2002533359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11392398P 1998-12-28 1998-12-28
US60/113,923 1998-12-28
PCT/US1999/031093 WO2000038518A1 (en) 1998-12-28 1999-12-28 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Publications (2)

Publication Number Publication Date
JP2002533359A true JP2002533359A (ja) 2002-10-08
JP2002533359A5 JP2002533359A5 (cg-RX-API-DMAC7.html) 2007-02-22

Family

ID=22352321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000590483A Pending JP2002533359A (ja) 1998-12-28 1999-12-28 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入

Country Status (5)

Country Link
EP (1) EP1139751A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002533359A (cg-RX-API-DMAC7.html)
AU (1) AU763049B2 (cg-RX-API-DMAC7.html)
CA (1) CA2356551A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000038518A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161704A (ja) * 2005-12-09 2007-06-28 Koshi Tei 神経損傷を処置するためのまたは神経細胞を再生するための組成物
JP2009544698A (ja) * 2006-07-25 2009-12-17 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
EP1870473A1 (en) * 2000-08-17 2007-12-26 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
ES2288993T3 (es) * 2000-08-17 2008-02-01 Keiya Ozawa Distribucion de factores angiogenicos mediada por virus adenoasociados.
EP1324780A4 (en) * 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
US20030022870A1 (en) * 2001-06-01 2003-01-30 Victor Dzau Methods of treating cardiac disorders
AU2003299204A1 (en) 2002-10-02 2004-04-23 The Johns Hopkins University Focal calcium channel modulation
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
CA2837322C (en) * 2011-05-26 2023-03-21 University Of Washington Cell and gene based methods to improve cardiac function
US12064470B2 (en) 2017-11-16 2024-08-20 Universite D'aix-Marseille FGF10 for the treatment of heart diseases
CA3099958A1 (en) 2018-04-16 2019-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating duchenne muscular dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792483A (en) * 1993-04-05 1998-08-11 Vickers, Inc. Injection molding machine with an electric drive
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010008664, KAPLITT,M.G. et al, "Long−term gene transfer in porcine myocardium after coronary infusion of an adeno−associated virus v", Ann Thorac Surg, 1996, Vol.62, No.6, p.1669−76 *
JPN6010008665, MAEDA,Y. et al, "Efficient gene transfer into cardiac myocytes using adeno−associated virus (AAV) vectors", J Mol Cell Cardiol, 199807, Vol.30, No.7, p.1341−8 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161704A (ja) * 2005-12-09 2007-06-28 Koshi Tei 神経損傷を処置するためのまたは神経細胞を再生するための組成物
JP2009544698A (ja) * 2006-07-25 2009-12-17 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
JP2014218509A (ja) * 2006-07-25 2014-11-20 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Also Published As

Publication number Publication date
EP1139751A4 (en) 2003-03-19
CA2356551A1 (en) 2000-07-06
WO2000038518A1 (en) 2000-07-06
AU763049B2 (en) 2003-07-10
AU2394200A (en) 2000-07-31
WO2000038518A9 (en) 2002-04-11
EP1139751A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
US7078387B1 (en) Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
JP3487597B2 (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
CN1136920C (zh) 基因转移介导的血管形成疗法
US5792453A (en) Gene transfer-mediated angiogenesis therapy
JP2004313198A (ja) 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入
EP1311699B1 (en) Adeno-associated virus-mediated delivery of angiogenic factors
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子:vegfの変異体
AU763049B2 (en) Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
CN100350979C (zh) 核酸和血管活性剂相组合用于加强的基因投递
US20250143624A1 (en) Ventricular Arrhythmias and Related Methods
WO1998013070A1 (en) Non-invasive administration of adeno-associated viral vectors
US6099831A (en) Viral recombinant vectors for expression in muscle cells
AU706050C (en) Gene transfer-mediated angiogenesis therapy
HK1094944A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU2006200170A1 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
HK1008979B (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100714